| Name | Title | Contact Details |
|---|
Cardinal Health Canada is a Concord, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Cambridge Technology is a Bedford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At EyeCare Partners, we are on a mission to reinvent eye care by creating a network of optometry and ophthalmology practices that bring together a wealth of expertise, resources and knowledge. While our partner practices have unique cultures, we present a united front through our shared best practices, clinical research and innovative solutions to vision health. We believe everyone deserves to see life with the best vision possible. With over 300 ophthalmologists and 700 optometrists nationwide, we are committed to making high-quality eye care easy, accessible and personalized. We are elevating eye care for everyone.
EG GILERO is the merger of trusted companies in the medical device industry whose roots go back decades. GILERO Biomedical, Medacys, InField Medical and the medical businesses of eNNOVEA and ValTech Holdings have been brought together by EGI, Inc. to create one vertically integrated resource for the medical device industry. EG GILERO is your single-source, trusted partner for design, development and manufacturing within the medical devices, drug delivery, and primary pharmaceutical packaging markets. With operations in the United States and Asia, EG GILERO is strategically positioned to provide the value added services our clients require in a competitive, ever-changing global marketplace. Together, we will accelerate your device timelines from concept to commercialization.
At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.